Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
LOS ANGELES, May 30, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Neurotrope, Inc. (“Neurotrope” or the “Company”) (Nasdaq:NTRP) concerning possible violations of federal securities laws between January 7, 2016 and April 28, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the July 17, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Neurotrope issued materially false and misleading statements and/or failed to disclose material information concerning the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” The underlying trial data contradicted these representations, as the top-line data relating to the 20-microgram dose of Bryostatin-1 failed to produce results that were statistically significant. Also, Neurotrope failed to disclose statements regarding the efficacy of the 40-microgram dose with regard to its primary and secondary endpoints. When this information was released, the Company’s shares fell in value, which harmed investors according to the Complaint.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
